PHASE 1b STUDY OF PTC596 IN COMBINATION WITHDACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT,UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORYLEIOMYOSARCOMA

Protocol: 
AAAS2818
Phase: 
I

PHASE 1b STUDY OF PTC596 IN COMBINATION WITHDACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT,UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORYLEIOMYOSARCOMA

The purpose of this study is to evaluate the effectiveness of a new
investigational drug, PTC596, used in combination with dacarbazine, for the
treatment of locally recurrent, unresectable or metastatic
relapsed/refractory leiomyosarcoma. The purpose of this study is to evaluate
whether adding PTC596 to dacarbazine is safe, and whether the combination
may work better than dacarbazine alone. Approximately 20 people will take
part in this study at 1 site in the US.

Are you Eligible? (Inclusion Criteria)

Are you 18 years of age or older?
Have you been diagnosed with unresectable or metastatic leiomyosarcoma?
Do you have measurable disease?
Are you able to swallow oral medication?
Has it been at least 4 weeks since your last surgery?

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States